Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
At the Annual Meeting of Stockholders of Achillion
Pharmaceuticals, Inc. (the Company) held on May23, 2017, the
Companys stockholders considered and voted upon the following
proposals at the meeting: (1)the election of each of Michael D.
Kishbauch, Robert L. Van Nostrand and Nicole Vitullo as the
Companys three ClassII directors for terms to expire at the
Companys 2020 Annual Meeting of Stockholders and until their
successors are duly elected and qualified; (2)the approval, on an
advisory basis, of the Companys executive compensation; (3)the
recommendation, on an advisory basis, of the frequency of future
executive compensation advisory votes; and (4)the ratification of
the selection of PricewaterhouseCoopers LLP as the Companys
independent registered public accounting firm for the fiscal year
ending December31, 2017.
Each proposal was approved by the requisite number of votes. The
results with respect to each matter voted upon are set forth
below.
(1) The Companys stockholders elected the nominees listed below
to the Companys Board of Directors, each to serve as a ClassII
director for a term to expire at the Companys 2020 Annual Meeting
of Stockholders and until their successors are duly elected and
qualified:
|
Director Nominee |
For | Withheld | BrokerNon-Votes | |||||||||
|
Michael D. Kishbauch |
89,216,946 | 5,034,805 | 22,857,322 | |||||||||
|
Robert L. Van Nostrand |
93,284,615 | 967,136 | 22,857,322 | |||||||||
|
Nicole Vitullo |
93,389,440 | 862,311 | 22,857,322 |
(2) The compensation of the Companys named executive officers was
approved on a non-binding advisory basis:
| For | Against | Abstain | BrokerNon-Votes | |||
| 92,586,346 | 1,185,394 | 480,011 | 22,857,322 |
(3) The stockholders recommended, in a non-binding advisory vote,
that future advisory votes on the compensation of the Companys
named executive officers be held every year:
| One Year | TwoYears | ThreeYears | Abstain | BrokerNon-Votes | ||||
| 85,723,472 | 157,799 | 8,130,098 | 240,382 | 22,857,322 |
Based on these results and consistent with the Boards previous
recommendation, the Board intends to hold future advisory votes
on the compensation of the Companys named executive officers
every year.
(4) The selection of PricewaterhouseCoopers LLP as the Companys
independent registered public accounting firm for the fiscal year
ending December31, 2017 was ratified:
| For | Against | Abstain | ||
| 115,846,606 | 817,403 | 445,064 |
About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Recent Trading Information
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed its last trading session up +0.01 at 4.14 with 710,525 shares trading hands.